Trials / Completed
CompletedNCT04004611
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab. The study lasted about 52 weeks and included up to 18 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Administered IV and SC |
Timeline
- Start date
- 2020-05-18
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
- First posted
- 2019-07-02
- Last updated
- 2024-03-26
- Results posted
- 2023-10-27
Locations
37 sites across 5 countries: United States, Canada, Israel, Japan, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04004611. Inclusion in this directory is not an endorsement.